VIDEO: Liso-cel could have ‘best shot’ at remission for double refractory CLL
In this video, Jakub Svoboda, MD, discusses updated data on the results of lisocabtagene maraleucel chimeric antigen receptor T-cell therapy on chronic lymphocytic leukemia, presented at ASCO Annual Meeting.
Svoboda, an associate professor of medicine at Hospital of the University of Pennsylvania, highlighted the study, which provided promising results from patients treated with lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) — also known as liso-cel — and showed durable responses among patients with CLL.
“I think that out of all of the other things in development for double refractory patients, perhaps the CAR-T has the best shot in resulting in long-term remission in some groups of patients,” Svoboda said.
Reference:
- Siddiqi T, et al. Abstract 7501. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Read more from Take Homes in Leukemia
View allRead more about